One in eight women worldwide lives with a condition that has long been misunderstood, underdiagnosed, and stigmatised (1). For decades, it carried a name that misled both patients and doctors: Polycystic Ovary Syndrome, or PCOS (2). The name suggested cysts on the ovaries were central, when in fact many women diagnosed had no cysts at all. What lay at the heart was a complex interplay of hormones, metabolism, and inflammation, and the label never reflected that (3). In May 2026, a global consensus published in The Lancet corrected the record, renaming the condition Polyendocrine Metabolic Ovarian Syndrome, or PMOS (2).

What’s in a name? Well, the consequences of the old name ran deep. Women were often told their struggles were “just fertility issues,” dismissed, fragmented across specialists, and left without answers, when in reality their condition was increasing their risk for insulin resistance, type 2 diabetes, cardiovascular disease, and mental health challenges (4). The name delayed care, limited research funding, and kept 70% of those affected from ever receiving a diagnosis. When the label sends doctors looking in the wrong place, the patient is left behind (5).

PMOS corrects this by reframing the condition as systemic, not just reproductive. To understand what the new name actually means, it helps to break it down word by word.

• Polyendocrine signals that multiple hormone systems are involved: insulin, androgens, neuroendocrine pathways, and ovarian hormones all play a role (6).
• Metabolic highlights the real-world impacts on weight, blood sugar, cardiovascular risk, and long-term disease progression (7).
• Ovarian acknowledges that the ovaries are still part of the picture, but they are not the whole story (8).

This renaming does not mean a new disease. It is the same condition, now described in a way that matches lived experience. For women, diagnosis will shift away from cyst-focused ultrasounds toward metabolic and hormonal screening. Treatment will expand beyond fertility clinics to include endocrinology, nutrition, and lifestyle medicine. For clinicians, it is a call to screen earlier and treat more holistically. For researchers, it opens funding streams that a misleading label had long kept closed (2).

In South Africa, where millions of women are affected (extrapolated from the global prevalence of 1 in 8), the stakes are especially high (1). This renaming offers a real opportunity to improve recognition in primary care, reduce inequality in access to treatment, and empower women to advocate for themselves and their health. Nutrition, insulin resistance, inflammation, and metabolic function have always been central to how the Noakes Foundation approaches chronic disease, and PMOS now gives that framework a globally recognised name to stand behind. The work ahead is to translate this moment into better outcomes on the ground, particularly for women who have historically been underserved by a system that did not fully understand what it was treating.

Language shapes care, and care shapes lives. PMOS is more than a new acronym; it is a new era in women’s health. One that finally tells the truth.

References

1.   Salari, N., Nankali, A., Ghanbari, A. H., Jafarpour, S., Ghasemi, H., Dokaneheifard, S., & Mohammadi, M. (2024). Global prevalence of polycystic ovary syndrome in women worldwide: A comprehensive systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 310(3), 1303–1314. https://doi.org/10.1007/s00404-024-07607-x 
2.   Teede, H., Khomami, M., Morman, R., Piltonen, T., & Dokras, A. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 405(10537), S0140-6736(26)00717-8
3.   Norman, R. J., & Teede, H. (2026). Polycystic ovary syndrome (PCOS) not linked to higher rate of abnormal ovarian cysts, study shows. ABC News. https://www.abc.net.au/news/health/2026-05-12/polycystic-ovary-syndrome-abnormal-ovarian-cysts/106
4.   Teede, H. J., Tay, C. T., Laven, J., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., M Redman, L., A Boyle, J., Norman, R. J., Mousa, A., Joham, A. E., & International PCOS Network (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and sterility, 120(4), 767–793. https://doi.org/10.1016/j.fertnstert.2023.07.025
5.   Naeem, I., Zehra, A., Rehman, F., Hussain, A., Hussain, A., Hussain, N., Waseem, M., Alqahtani, R. M., Shamlan, G., Ahmed, I. A. M., Manzoor, M. F., & Abdullahi, M. A. (2025). Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches. Journal of ovarian research, 18(1), 219. https://doi.org/10.1186/s13048-025-01741-z
6.   Deng, H., Chen, Y., Xing, J., Zhang, N., & Xu, L. (2024). Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome. Frontiers in immunology, 15, 1470283. https://doi.org/10.3389/fimmu.2024.1470283
7.   Chen, X., Wan, Y., & Xie, L. (2025). Insulin resistance in polycystic ovary syndrome: pathophysiological mechanisms of menstrual dysfunction and evidence-based treatment strategies. Biology of reproduction, 113(6), 1340–1354. https://doi.org/10.1093/biolre/ioaf197
8.   Dalamaga, M. (2026). What’s in a name? From PCOS to polyendocrine metabolic ovarian syndrome: A metabolic reframing, promise, controversies, and challenges ahead. Metabolism Open, Article 100479. https://doi.org/10.1016/j.metop.2026.100479